BioSpace News Archive

Relay Therapeutics, Inc. is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday May 20, 2021 at 11:20am ET.

In accordance with the newsletter that was published the 5th of January 2021, Erik Penser Bank has now begun the implementation of a number of commissioned analyses, the first of which has been published and is available on ChemoTech’s website in English

Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021

Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in two upcoming investor conferences

Metagenomi, a gene editing company, presented data on their novel CRISPR-associated transposases system that allows for precise integration of large DNA fragments into genomes at the 24th Annual Meeting of the American Society of Gene and Cell Therapy, which is being held virtually.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that management will participate in a Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit on Friday, May 21st at 10:00AM ET.

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the first quarter ended March 31, 2021

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate developments.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it will host a key opinion leader (KOL) webinar on melanocortin agonists for treating ocular indications, with a primary focus on PL9643, the Company’s lead asset.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L. Hannah, M.D. to its Board of Directors.